Five years after taking the job, Teva Pharmaceutical Industries CEO Shlomo Yanai has announced his resignation, marking the end of a tenure in which the company failed to diminish its dependence on profit from flagship multiple sclerosis drug Copaxone.
Yanai will be replaced in May by Bristol-Myers Squibb executive Jeremy Levin, the first non-Israeli to lead the company. Yanai, 59, wanted "to move on to a new phase in his career," Teva said yesterday.
Tuesday, January 03, 2012
Teva getting its first non-Israeli CEO as Shlomo Yanai resigns
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment